# US 2003/0212128 A1 · Crystalline composition containing escitalopram

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212128 A1
- Document ID: US20030212128A1
- Status: Published application
- Kind: A1
- Application number: 10/403,453
- Filed: 2003-03-31
- Published: 2003-11-13
- Earliest claimed: 2001-07-31
- Assignees: H. Lundbeck A/S
- Inventors: Troels Volsgaard Christensen; Ken Liljegren; Michiel Onne Elema; Lene Andresen; Shashank Mahashabde; Sebastian P. Assenza
- Web page: https://patentgrep.com/patent/US20030212128A1

## CPC

- C07D 307/87: Benzo [c] furans; Hydrogenated benzo [c] furans
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.

## Claims

### Claim 1

Crystalline particles of escitalopram oxalate having a median particle size of at least 40 μm.

### Claim 2 (depends on 1)

The crystalline particles of claim 1 wherein the medial particle size is from 50-200 μm.

### Claim 3

A method for the manufacture of crystalline particles of escitalopram oxalate, which comprises
(a) dissolving escitalopram oxalate to form a solution of escitalopram oxalate;
(b) gradually cooling the solution of escitalopram oxalate to a predetermined temperature while maintaining a controlled cooling rate;
(c) adding crystals of escitalopram oxalate during the cooling of step (b);
(d) holding the solution at the predetermined temperature; and
(e) isolating crystalline particles of escitalopram oxalate from the solution.

### Claim 4 (depends on 3)

The method of claim 3 wherein in step (a) escitalopram oxalate is dissolved in a solvent system.

### Claim 5 (depends on 3)

The method of claim 3 wheren in step (c) the solution is cooled from a first temperature to a second temperature.

### Claim 6 (depends on 3)

The method of claim 3 wherein the median particle size of the crystalline particles is at least 40 μm.

### Claim 7 (depends on 3)

The method of claim 3 wherein the median particle size of the crystalline particles is from 50-200 μm.

### Claim 8 (depends on 4)

The method of claim 4 wherein the solvent system comprises at least one alcohol and optionally water.

### Claim 9 (depends on 8)

The method of claim 8 wherein the solvent system comprises ethanol.

### Claim 10 (depends on 4)

The method of claim 4 wherein the solute:solvent weight ratio is between about 0.05:1 and 0.6:1.

### Claim 11 (depends on 4)

The method of claim 4 wherein the solute:solvent weight ratio is between about 0.1:1 and 0.5:1.

### Claim 12 (depends on 4)

The method of claim 4 wherein the solute:solvent weight ratio is between about 0.2:1 and 0.4:1.

### Claim 13 (depends on 5)

The method of claim 5 wherein the first temperature is between about 50° C. and the refluxing temperature of the solvent system.

### Claim 14 (depends on 5)

The method of claim 5 wherein the first temperature is between about 60° C. and the refluxing temperature of the solvent system.

### Claim 15 (depends on 5)

The method of claim 5 wherein the first temperature is between about 70° C. and the refluxing temperature of the solvent system.

### Claim 16 (depends on 5)

The method of claim 5 wherein the second temperature is between about 0° C. and 20° C.

### Claim 17 (depends on 5)

The method of claim 5 wherein the second temperature is between about 0° C. and 15° C.

### Claim 18 (depends on 5)

The method of claim 5 wherein the second temperature is between about 7° C. and 15° C.

### Claim 19 (depends on 3)

The method of claim 3 wherein the controlled cooling rate comprises an initial cooling period during which the cooling rate does not exceed 0.6° C. per minute.

### Claim 20 (depends on 19)

The method of claim 19 wherein the initial cooling period comprises the time between the start of the cooling period and the time at which the temperature is below 60° C.

### Claim 21 (depends on 19)

The method of claim 19 wherein the initial cooling period comprises the time between the start of the cooling period and the time at which the temperature is below 50° C.

### Claim 22 (depends on 19)

The method of claim 19 wherein the initial cooling period comprises the time between the start of the cooling period and the time at which the temperature is below 40° C.

### Claim 23 (depends on 19)

The method of claim 19 wherein the cooling rate of the solution comprises from 0.2 to 0.4° C. per minute.

### Claim 24 (depends on 3)

The method of claim 3 which comprises adding crystals of escitalopram oxalate at least two times during the cooling of step (b).

### Claim 25 (depends on 3)

The method of claim 3 which comprises holding the solution at the predetermined temperature for at least one hour.

### Claim 26 (depends on 3)

The method of claim 3 which comprises holding the solution at the predetermined temperature for 4 to 24 hours.

### Claim 27 (depends on 3)

The method of claim 3, which comprises holding the solution at the predetermined temperature for 6 to 12 hours.

### Claim 28 (depends on 3)

The method of claim 3, wherein step (e) comprises isolating the crystalline particles of escitalopram oxalate by solid/liquid separation techniques.

### Claim 29 (depends on 28)

The method of claim 28, wherein the solid/liquid separation techniques comprise filtration.

### Claim 30 (depends on 1)

A solid unit dosage form comprising the crystalline particles of escitalopram oxalate of claim 1.

### Claim 31 (depends on 2)

A solid unit dosage form comprising the crystalline particles of escitalopram oxalate of claim 2.

### Claim 32 (depends on 30)

The solid unit dosage form of claim 30, which comprises a tablet prepared by direct compression of a mixture of escitalopram oxalate and pharmaceutically acceptable excipients.

### Claim 33 (depends on 32)

The solid unit dosage form of claim 32, wherein the tablet is coated.

### Claim 34 (depends on 30)

The solid unit dosage form of claim 30, which is prepared by filling a hard gelatin capsule with a mixture of escitalopram oxalate and pharmaceutically acceptable excipients.

### Claim 35 (depends on 30)

The solid unit dosage form of claim 30, which does not contain a binder.

### Claim 36 (depends on 30)

The solid unit dosage form of claim 30, which comprises 1-30% w/w active ingredient calculated as escitalopram base.

### Claim 37 (depends on 30)

The solid unit dosage form of claim 30, which comprises 4-20% w/w active ingredient calculated as escitalopram base.

### Claim 38 (depends on 30)

The solid unit dosage form of claim 30, which comprises 6-10% w/w active ingredient calculated as escitalopram base.

### Claim 39 (depends on 30)

The solid unit dosage form of claim 30, which further comprises a filler selected from the group consisting of lactose, sugars, calcium phosphates, starch, modified starches, microcrystalline cellulose, calcium sulfate and calcium carbonate.

### Claim 40 (depends on 39)

The solid unit dosage form of claim 39, wherein the filler comprises a sugar selected from the group consisting of sorbitol, mannitol, dextrose and sucrose.

### Claim 41 (depends on 39)

The solid unit dosage form of claim 39, wherein the filler comprises a calcium phosphate selected from the group consisting of dibasic, tribasic, hydrous and anhydrous calcium phosphate.

### Claim 42 (depends on 39)

The solid unit dosage form of claim 39, wherein the filler comprises microcrystalline cellulose.

### Claim 43 (depends on 42)

The solid unit dosage form of claim 42, wherein the microcrystalline cellulose is selected from the group consisting of ProSolv SMCC90 and Avicel PH 200.

### Claim 44 (depends on 30)

The solid unit dosage form of claim 30, further comprising a lubricant.

### Claim 45 (depends on 44)

The solid unit dosage form of claim 44, wherein the lubricant comprises a member selected from the group consisting of metallic stearates, stearic acid, wax, hydrogenated vegetable oil, talc and colloidal silica.

### Claim 46 (depends on 45)

The solid unit dosage form of claim 45, wherein the lubricant comprises a metallic stearate selected from the group consisting of magnesium, calcium and sodium stearate.

### Claim 47 (depends on 45)

The solid unit dosage form of claim 45, wherein the lubricant comprises a member selected from the group consisting of talc, magnesium stearate and calcium stearate.

### Claim 48 (depends on 45)

The solid unit dosage form of claim 45, wherein the lubricant comprises talc and magnesium stearate.

### Claim 49 (depends on 48)

The solid unit dosage form of claim 48, wherein the magnesium stearate is present in a weight percent of 0.4% to 2%, calculated on the weight of the solid dosage form.

### Claim 50 (depends on 48)

The solid unit dosage form of claim 48, wherein the magnesium stearate is present in a weight percent of 0.7% to 1.4%, calculated on the weight of the solid dosage form.

### Claim 51 (depends on 30)

The solid unit dosage form of claim 30, which is substantially free of lactose.
